Physician profile
Shadiqul Hoque
NPI 1487918702
$1,375.02
in general payments reported to CMS, 2019-2025
33 companies · $917 in 2025
The $917 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $279 · 2024: $179 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $106.45 | 2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $94.97 | 2023 | Reblozyl |
| Kite Pharma, INC. | $92.12 | 2023 | Yescarta |
| Glaxosmithkline, LLC. | $91.92 | 2023 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $80.17 | 2025 | |
| Genentech USA, INC. | $70.07 | 2024-2025 | Itovebi, Tecentriq, Tecentriq Hybreza |
| Janssen Biotech, INC. | $65.87 | 2025 | Erleada, Rybrevant |
| Eisai INC. | $55.15 | 2024 | |
| Merck Sharp & Dohme LLC | $47.22 | 2025 | Keytruda, Welireg |
| Abbvie INC. | $46.97 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.55 | 2025 | Fruzaqla, Vpriv |
| Incyte Corporation | $45.00 | 2025 | Jakafi |
| Galvanize Therapeutics, INC | $40.00 | 2025 | Aliya System |
| Sobi, INC | $39.09 | 2025 | |
| Pfizer INC. | $38.20 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.61 | 2025 | |
| Novocure INC. | $32.82 | 2025 | Optune Lua (Novottf-200t) |
| Alexion Pharmaceuticals, INC. | $31.47 | 2025 | Ultomiris |
| Genzyme Corporation | $31.07 | 2025 | |
| Agios Pharmaceuticals, INC. | $26.31 | 2025 | Pyrukynd |
| Tersera Therapeutics LLC | $25.86 | 2025 | Xermelo |
| Gilead Sciences, INC. | $24.98 | 2025 | Trodelvy |
| Melinta Therapeutics, LLC | $21.08 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Pharmacosmos Therapeutics INC. | $21.00 | 2024 | Monoferric |
| Ferring Pharmaceuticals INC. | $20.65 | 2025 | Adstiladrin |
| Kyowa Kirin, INC. | $20.17 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.81 | 2025 | Danziten |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.42 | 2025 | |
| Stemline Therapeutics INC. | $19.01 | 2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $18.59 | 2025 | Romvimza, Qinlock |
| Daiichi Sankyo INC. | $17.33 | 2025 | Enhertu |
| Shield Therapeutics INC | $16.63 | 2025 | |
| Puma Biotechnology, INC. | $14.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadiqul Hoque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.